Anthem Biosciences Limited Earnings Summary — Q4 FY2026

• Q4 Consolidated Net Profit surged 45% YoY to ₹1,891.58 million, driven by robust performance in discovery and manufacturing segments.
• The Board recommended a final dividend of ₹2.00 per share (100% of face value) for FY2026.
• Successful initial public offering (IPO) during the year, with shares listed on July 21, 2025.
• Operating margins showed significant expansion during the quarter, reaching approximately 38.8% compared to the prior year period.
• The company recognized a net expense of ₹240.13 million as an exceptional item related to newly notified labor codes in India.
• Anthem strengthened its capital base through the allotment of 1.48 million equity shares under its 2024 Employee Stock Option Plan.
• Consolidated balance sheet remains healthy with total assets growing to ₹35,308.46 million from ₹28,355.64 million YoY.

Management is focusing on scaling commercial-scale manufacturing and expanding high-value technology platforms including RNAi and Antibody-Drug Conjugates (ADCs).

Improving

The transition to a public entity has coincided with margin expansion and strong double-digit growth in both revenue and profitability.

Anthem is positioned for continued high-value growth through its integrated Chemistry and Biology capabilities. Strategic capacity expansions in fermentation and custom synthesis are expected to drive future revenue cycles.